Thyroid medication recall upgraded to FDA's highest risk level
Published September 24, 2026 2:52 PM CDT article Vitruvias Therapeutics, Inc., issued a recall on a single lot of its Thyroid Tablets.
Published September 24, 2026 2:52 PM CDT article Vitruvias Therapeutics, Inc., issued a recall on a single lot of its Thyroid Tablets. (FDA) A thyroid medication recall announced last month has been upgraded to the highest risk level allotted by federal regulators, according to the Food and Drug Administration.
Vitruvias Therapeutics Inc. voluntarily recalled one lot of its Thyroid Tablets, USP 30 mg, in late August because "testing confirmed the potential for the product to be superpotent." On Tuesday, the recall was upgraded to Class I, "a situation in which there is a reasonable probability that the use of or exposure to a violative product will cause serious adverse health consequences or death." Thyroid medication recalled By the numbers: The lot number for the recalled thyroid tablets is 504950.
First reported by Fox 7 Austin.
The Cali Reporter newsletter
The stories worth your time.
California, the country, and what comes next. Join our free newsletter for reporting that keeps you informed.
More in Health & Medicine
- Brain Energy Mismatches in Schizophrenia
A new study explores the potential role of energy bottlenecks in brain cells in explaining fragmented experiences of time, space, and self in schizophrenia.
- Brazil Reports First Mpox Death in 2026
Brazil has recorded its first mpox-related death in 2026, but public health officials are not classifying the current surge in cases as an outbreak, according to the Fiocruz Institute.
- Personalized Therapies for IBD May Target Specific Harmful Gut Bacteria
A study led by Dr. Lukas Mager and Prof. Kathy McCoy has identified two gut bacteria that promote inflammation in inflammatory bowel disease, opening the door for personalized treatments.